Introduction
Hematopoietic SCT (HSCT) is a potentially curative treatment for a variety of acquired and congenital disorders of children and young adults. According to the Center for International Blood and Marrow Transplant Research, there are more than 2000 pediatric allogeneic transplants performed each year worldwide. 1 It has been documented that up to 44% of these children require transfer to the pediatric intensive care unit (PICU) after HSCT. [2] [3] [4] Respiratory failure, secondary to pulmonary complications, is the most frequent reason for PICU admission, accounting for 35-88% of transfers. 2, 4, 5 Although debated, 6 several recent studies suggest improved survival over time in ventilated HSCT children with survival rates exceeding 50% being reported. 3, 7, 8 The reasons for this improvement have not been clearly established and are likely multifactorial.
For outcomes of critically ill HSCT children to continue to improve, there is a need for research to advance beyond case reports and retrospective series and progress into protocolized trials with prospectively collected data. To date, clinical research efforts have been hindered by the uniqueness of this patient population, the relatively small number of cases cared for at any one center, the high risk of mortality and the need for multidisciplinary care. These characteristics have the potential to lead to important variation in care practices complicating study design and influencing the willingness of centers to participate in prospective clinical trials. To begin to overcome these obstacles and develop effective research trials among critically ill pediatric HSCT patients, a better understanding of the epidemiology of this patient population and the variances in their care is needed. Therefore, a survey was developed to assess the care of critically ill pediatric HSCT patients across Canada and the United States. The acquisition of such information may be helpful in designing effective future research among this unique population. Center for International  Blood and Marrow Transplant Research, unpublished  data, 2008 ) and the 6 other high-volume centers from the Blood and Marrow Transplant Information Network (BMT InfoNet) website. 9 These 30 centers performed over 75% of all pediatric HSCT in the United States in 2005 and included centers from each of the nine regional divisions identified by the United States Census Bureau. Four exclusively pediatric Canadian HSCT centers were also identified through BMT InfoNet.
Materials and methods

A North
The survey was developed by the Pediatric Acute Lung Injury and Sepsis Investigators Network Oncology/HSCT subgroup. It was piloted at six member institutions of the subgroup and amended accordingly before distribution to the highest volume pediatric HSCT centers in North America. All centers in the United States and three of the four Canadian centers were certified by the Foundation for the Accreditation of Cellular Therapies and members of the Children's Oncology Group. For centers reporting pediatric specific data, the number of transplants performed at the surveyed centers ranged from 26 to 196 in 2006. 9 The Pediatric Acute Lung Injury and Sepsis Investigator Network is a multi-institutional trials group comprised more than 78 pediatric centers from the United States and Canada with an ever-expanding track record of performing successful clinical trials. 10 The Oncology/HSCT subgroup consists of both pediatric critical care medicine (PCCM) and pediatric HSCT physicians. It was recently developed with the goal of reducing mortality in oncology and HSCT pediatric patients who develop acute lung injury (ALI) and sepsis.
Two individuals were randomly identified at each institution to complete the survey; one PCCM physician and one pediatric HSCT physician. The PCCM physicians were given a survey addressing both general aspects of their critical care program and the clinical approach to critically ill HSCT patients. The HSCT physicians were asked questions pertaining to their transplant program including the level of monitoring and critical care therapies offered on the HSCT unit. A four-point Lickert scale was used for most of the clinical questions (Appendices 1 and 2 in Supplementary information). The survey was conducted electronically using SurveyMonkey technology with a provision for hard copy submission, if the surveyed center preferred to do so. The initial contact was made by e-mail with a link to an anonymous SurveyMonkey site. If no response to the survey was obtained, an automatic followup e-mail was sent, and subsequently, a phone call was made to the center.
For analysis, descriptive statistics alone were used and data were expressed as frequencies (%). Lickert scale responses were collapsed into two categories (always/ commonly and rarely/never) to highlight trends in practices when deemed appropriate. Not all individuals answered all questions, and thus, there is variation in the number of responses. Institutional Review Board approval was obtained at the sites from which the survey was developed and/or administered (Pennsylvania State University, Centre Hospitalier Universitaire Ste-Justine and the Children's Hospital of Wisconsin).
Results
In all, 33 of 34 (97%) PCCM and 30 of 34 (88%) pediatric HSCT physicians responded to the survey. Eighty-three percent of the surveyed centers had more than 100 pediatric beds; 24% had between 201 and 300 beds, 20% with 301-400 beds and 12% with more than 400 beds. Seventynine percent of the PICUs had 20 or more beds and nearly all of them (91%) admitted over 1000 patients each year. Eighty-eight percent of the surveyed centers had a fellowship program in PCCM, 90% had a fellowship program in pediatric hematology/oncology and 45% specifically in pediatric HSCT.
Responses from HSCT physicians regarding care offered on the oncology/HSCT unit are summarized in Table 1 . Fourteen (48%) HSCT physicians responded that central venous pressure was never monitored on the oncology/ HSCT unit. In terms of hemodynamic support, five (17%) HSCT physicians reported that there were restrictions on the number of fluid boluses that could be given on the oncology/HSCT unit although a specific amount of fluid was not solicited in the survey. In most centers, a dopamine infusion of X10 mcg/kg/min mandated a transfer to the PICU evidenced by 8 (38%) and 11 (52%) HSCT physicians reporting that the maximum dopamine dose allowed on their oncology/HSCT unit was 3 and 9 mcg/kg/ min, respectively. Regarding respiratory services, two (7%) HSCT physicians answered that non-invasive positive pressure ventilation was always offered on the oncology/ HSCT unit. Respondents reported that the critical care service performs consults on HSCT patients outside of the PICU in 76% of the surveyed centers. However, 75% of HSCT physicians acknowledged that there were no written guidelines regulating PCCM consultations, and thus, there existed variation in the criteria that prompted such a consultation ( Figure 1 ). Eighteen (67%) HSCT physicians responded that a hemoglobin level of 8 g per 100 mL is used as a trigger for transfusion of packed RBCs among noncritically ill patients. Four (15%) HSCT physicians reported that 7 g per 100 mL is their transfusion trigger, while one HSCT physician each answered 9 and 10 g per 100 mL. Two HSCT physicians responded that they use no pre-defined transfusion trigger.
Responses from PCCM physicians addressing therapies provided to HSCT patients once they have been transferred to the PICU are highlighted in Table 2 . Although the study revealed that HSCT patients admitted to the PICU are comanaged by HSCT and PCCM physicians 72% of the time, only the latter were surveyed regarding critical care services offered in the PICU. The surveyed centers varied with regard to the interventions attempted before intubating patients with ALI, but nearly all centers reported using non-invasive positive pressure ventilation, a 100% nonrebreather mask and/or aggressive diuresis (Figure 2 ).
More than half of the centers also reported using renal replacement therapy (64%) and/or corticosteroids (61%) before intubation with one-third administering etanercept. Figure 1 The figure depicts the criteria used to prompt a PCCM consultation. Each center was asked to select all criteria that applied. This consultation did not necessarily mandate a transfer to the pediatric intensive unit. The y axis represents the percentage of responding centers that selected that specific criterion. The x axis lists the criteria surveyed. Respiratory support indicates a consult to assist with the management of a respiratory problem. Hemodynamic monitoring indicates a consult for invasive hemodynamic monitoring (that is, central venous pressure monitoring, arterial catheter monitoring, and so on). Vasoactive infusion indicates a consult because of the need for a vasoactive infusion. RRT indicates a consult because of the need for renal replacement therapy. Procedure indicates a consult for a specific procedure (that is, central venous catheter placement, sedation for a procedure, thoracentesis, and so on). Nursing care indicates a consult for nursing care needs that exceed the limit of the oncology/HSCT unit. protocol for the Children's Oncology Group sponsored study of etanercept for idiopathic pneumonia syndrome. When asked if invasive mechanical ventilation was offered as a time-limited trial (that is, the use of mechanical ventilation is re-evaluated within a pre-specified time period for HSCT patients with ALI), 28% of PCCM physicians reported always as opposed to 13% who answered never. In the event of failure of conventional therapy, 9 (28%) and 19 (58%) PCCM physicians respectively reported that they never use surfactant or extracorporeal membrane oxygenation as potential rescue therapies for HSCT patients with ALI.
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Discussion
On the basis of a review of the literature, this appears to be the first survey focused specifically on the care of critically ill pediatric HSCT patients across Canada and the United States. The high response rate by HSCT (88%) and PCCM (97%) physicians provides useful data on the care administered to these children when they become critically ill. For example, the survey suggests that 79% of the centers rarely or never perform non-invasive positive pressure ventilation on the general oncology/HSCT unit. However, all PCCM physicians who responded to the survey reported that they provide non-invasive positive pressure ventilation to these patients with ALI before intubation. In addition, two-thirds acknowledged offering invasive mechanical ventilation as a time-limited trial and 91% commonly support this population with high-frequency oscillatory ventilation when failing conventional therapy. This information may be helpful in the design of future clinical trials.
Analysis of the surveyed data suggested a close collaboration between the HSCT and PCCM physicians. This collaboration initially occurs on the oncology/HSCT unit with approximately three-quarters of the surveyed centers reporting that their critical care service will provide input on HSCT patients outside of the PICU. This collaboration appears to continue after transfer to the PICU as these patients are reported to be co-managed by the HSCT and critical care services 72% of the time. The potential benefit of such a multispecialist approach has been previously purported. 3, 11, 12 Furthermore, it has also been suggested that an earlier transfer to the PICU might contribute to improved outcomes among these patients. 3, 13 Data suggesting that admission rates for HSCT patients have risen since the year 2000, 5 in conjunction with data showing that fewer HSCT patients have required mechanical ventilation since that time, support that trend in care. 6 Data obtained through the survey also suggest that there is variation in the approach to pediatric HSCT patients when they become critically ill. This variation applies to therapies provided both outside and within the PICU. For example, although most centers are willing to provide PICU consultation on the oncology/HSCT unit, the criteria that prompt such a consultation vary widely. In addition, although nearly three-quarters of the centers use dopamine infusions on the oncology/HSCT unit, the maximum dopamine dose allowed varies widely. Moreover, after transfer to the PICU, variation exists in the selection of therapies provided by PCCM physicians to HSCT patients. For instance, for the patient with ALI failing conventional ventilation, the use of high-frequency oscillatory ventilation and renal replacement therapy appears to be common practice, while the administration of surfactant is more limited in spite of the literature support of its potential benefit in the immunocompromised population. 14, 15 Variation in clinical practice also appears to be present in the supportive care of non-critically ill HSCT children. In the survey, hemoglobin levels ranging from 7 to 10 g per 100 mL were reported by HSCT physicians as their threshold to justify a transfusion of packed RBCs in a non-critically ill patient. A hemoglobin threshold of 7 g per 100 mL is recommended for pediatric patients whose condition is stable in the PICU, 16 although there are no current recommendations pertaining specifically to critically ill HSCT children.
Although beyond the scope of this survey, several potential explanations may be offered to account for the variability in care practices. To begin, there is a wide spectrum of relatively unique infectious and non-infectious complications that occur in critically ill HSCT recipients. Combined with the relatively small number of patients cared for at any one institution, there is a limited exposure and experience with any of these morbidities. Without evidenced-based guidelines, decisions regarding the care of critically ill HSCT patients become subjective and vary according to institution and even between individual physicians at the same institution. This may be particularly true for PCCM physicians secondary to their frequent rotations in care. Consequently, there is a need for multicenter studies to identify best patient care plans. By identifying care variations across institutions, this information may be used to advance care through prospective, protocolized study.
A number of trials have shown that variation in clinical practice, along with the cost of intensive care unit medicine, may be reduced with the use of decision-support tools. [17] [18] [19] Furthermore, it has been reported that protocol-based therapies may enhance and maintain the quality and efficiency of care thereby resulting in decreased morbidity and mortality. 17, 18 The high response rate to this survey suggests a general motivation of physicians from both the HSCT and PCCM services to improve the outcomes of the critically ill pediatric HSCT patient. Such motivation will clearly be needed to establish clinical guidelines and protocolized treatment plans.
Although this study incurs the limitations of many survey studies, it is strengthened by the broad and diverse input of physicians caring for the critically ill pediatric HSCT population across North America. However, it is important to note that the survey sought the input of only one PCCM and HSCT physician at each site, and thus, their responses might not have accurately represented those of their colleagues or their institution. Moreover, only the largest HSCT centers were targeted for the survey. By eliminating the smaller volume centers, an even broader range of clinical approaches may have been missed. In addition, no attempt was made to discern practice differences between exclusively pediatric centers and combined pediatric and adult programs. Furthermore, the data collected was only survey information with no verification of the data provided. For example, only two centers reported ventilating through a tracheostomy tube on the HSCT/oncology unit while four reported ventilating through an endotracheal tube. These numbers merit verification as it appears likely that more centers would be willing to ventilate through a tracheostomy tube rather than through a less secure endotracheal tube. Alternatively, the responses may represent a greater willingness to subject pediatric HSCT patients to a less invasive, less secure procedure than the more invasive, albeit more secure, tracheostomy tube. Although the anonymous nature of the survey prevented such verification, the data provide a stimulus for further discussion.
In spite of these limitations, this survey provides insight on the care of critically ill pediatric HSCT patients across Canada and the United States. The responses obtained suggest that significant variability exists among centers on the clinical approach to these children. These results provide a foundation from which protocolized therapies may be developed. The development of protocolized, prospective trials may advance the care of these children and reduce the substantial mortality currently experienced by this patient population.
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